Vertex Pharmaceuticals (VRTX) Research & Development (2009 - 2026)

Vertex Pharmaceuticals' Research & Development history runs 18 years deep, the most recent figure standing at $961.6 million for Q1 2026.

• On a quarterly basis, Research & Development fell 1.85% year-over-year to $961.6 million in Q1 2026; TTM through Mar 2026 was $3.9 billion, a 1.85% increase from a year earlier, with the FY2025 full-year figure at $3.9 billion, up 7.69% from the prior year.
• Research & Development eased to $961.6 million in Q1 2026 per VRTX's latest filing, from $973.7 million in the prior quarter.
• Across five years, Research & Development topped out at $998.7 million in Q4 2024 and bottomed at $600.1 million in Q2 2022.
• The 5-year median for Research & Development is $824.6 million (2023), against an average of $835.6 million.
• Across the five-year window, Research & Development surged 38.12% in 2022 and dropped 2.5% in 2025, its largest moves.
• Year by year, Research & Development stood at $694.1 million in 2022, then climbed by 18.8% to $824.6 million in 2023, then gained by 21.11% to $998.7 million in 2024, then dropped by 2.5% to $973.7 million in 2025, then declined by 1.24% to $961.6 million in 2026.
• Per Business Quant, the three latest VRTX Research & Development figures stand at $961.6 million (Q1 2026), $973.7 million (Q4 2025), and $977.7 million (Q3 2025).